Corrigendum: Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1611591/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850271822392590336 |
|---|---|
| author | Wei Ren Hanyu Zhang Yixin Li Wu Sun Hexiang Peng Huangda Guo Tianjiao Hou Mengying Wang Mengying Wang Zhendong Hu Tao Wu Tao Wu Baorui Liu |
| author_facet | Wei Ren Hanyu Zhang Yixin Li Wu Sun Hexiang Peng Huangda Guo Tianjiao Hou Mengying Wang Mengying Wang Zhendong Hu Tao Wu Tao Wu Baorui Liu |
| author_sort | Wei Ren |
| collection | DOAJ |
| format | Article |
| id | doaj-art-d5253ad0650f432ba220ea38afc27af3 |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-d5253ad0650f432ba220ea38afc27af32025-08-20T01:52:06ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-05-011610.3389/fimmu.2025.16115911611591Corrigendum: Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysisWei Ren0Hanyu Zhang1Yixin Li2Wu Sun3Hexiang Peng4Huangda Guo5Tianjiao Hou6Mengying Wang7Mengying Wang8Zhendong Hu9Tao Wu10Tao Wu11Baorui Liu12The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, ChinaThe Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, ChinaKey Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, ChinaDepartment of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, ChinaDepartment of Esophageal Surgery, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, ChinaKey Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, ChinaThe Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, Chinahttps://www.frontiersin.org/articles/10.3389/fimmu.2025.1611591/fullPD-1/PD-L1 inhibitoresophageal squamous cell carcinomameta-analysisimmunotherapycombined positive score |
| spellingShingle | Wei Ren Hanyu Zhang Yixin Li Wu Sun Hexiang Peng Huangda Guo Tianjiao Hou Mengying Wang Mengying Wang Zhendong Hu Tao Wu Tao Wu Baorui Liu Corrigendum: Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis Frontiers in Immunology PD-1/PD-L1 inhibitor esophageal squamous cell carcinoma meta-analysis immunotherapy combined positive score |
| title | Corrigendum: Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis |
| title_full | Corrigendum: Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis |
| title_fullStr | Corrigendum: Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis |
| title_full_unstemmed | Corrigendum: Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis |
| title_short | Corrigendum: Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis |
| title_sort | corrigendum efficacy and safety of pd 1 pd l1 inhibitors as first line treatment for esophageal squamous cell carcinoma a systematic review and meta analysis |
| topic | PD-1/PD-L1 inhibitor esophageal squamous cell carcinoma meta-analysis immunotherapy combined positive score |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1611591/full |
| work_keys_str_mv | AT weiren corrigendumefficacyandsafetyofpd1pdl1inhibitorsasfirstlinetreatmentforesophagealsquamouscellcarcinomaasystematicreviewandmetaanalysis AT hanyuzhang corrigendumefficacyandsafetyofpd1pdl1inhibitorsasfirstlinetreatmentforesophagealsquamouscellcarcinomaasystematicreviewandmetaanalysis AT yixinli corrigendumefficacyandsafetyofpd1pdl1inhibitorsasfirstlinetreatmentforesophagealsquamouscellcarcinomaasystematicreviewandmetaanalysis AT wusun corrigendumefficacyandsafetyofpd1pdl1inhibitorsasfirstlinetreatmentforesophagealsquamouscellcarcinomaasystematicreviewandmetaanalysis AT hexiangpeng corrigendumefficacyandsafetyofpd1pdl1inhibitorsasfirstlinetreatmentforesophagealsquamouscellcarcinomaasystematicreviewandmetaanalysis AT huangdaguo corrigendumefficacyandsafetyofpd1pdl1inhibitorsasfirstlinetreatmentforesophagealsquamouscellcarcinomaasystematicreviewandmetaanalysis AT tianjiaohou corrigendumefficacyandsafetyofpd1pdl1inhibitorsasfirstlinetreatmentforesophagealsquamouscellcarcinomaasystematicreviewandmetaanalysis AT mengyingwang corrigendumefficacyandsafetyofpd1pdl1inhibitorsasfirstlinetreatmentforesophagealsquamouscellcarcinomaasystematicreviewandmetaanalysis AT mengyingwang corrigendumefficacyandsafetyofpd1pdl1inhibitorsasfirstlinetreatmentforesophagealsquamouscellcarcinomaasystematicreviewandmetaanalysis AT zhendonghu corrigendumefficacyandsafetyofpd1pdl1inhibitorsasfirstlinetreatmentforesophagealsquamouscellcarcinomaasystematicreviewandmetaanalysis AT taowu corrigendumefficacyandsafetyofpd1pdl1inhibitorsasfirstlinetreatmentforesophagealsquamouscellcarcinomaasystematicreviewandmetaanalysis AT taowu corrigendumefficacyandsafetyofpd1pdl1inhibitorsasfirstlinetreatmentforesophagealsquamouscellcarcinomaasystematicreviewandmetaanalysis AT baoruiliu corrigendumefficacyandsafetyofpd1pdl1inhibitorsasfirstlinetreatmentforesophagealsquamouscellcarcinomaasystematicreviewandmetaanalysis |